Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 9:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 813 matching trials from the live ClinicalTrials.gov search.
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
GTS21/Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Text- Messaging, Treatment as usual
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Interventions
Atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
8
States / cities
Rolling Hills Estate, California • Maitland, Florida • Miami, Florida + 5 more
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810 (18 mg), SPN-810 (36 mg), Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
28
States / cities
Rogers, Arkansas • Culver City, California • Glendale, California + 22 more
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention, Homework Support Intervention (HSI)
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 15 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
ADHD
Interventions
Stimulant Diversion Prevention (SDP)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Autism, Attention Deficit Hyperactivity Disorder
Interventions
Transcranial Photobiomodulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AKL-T01
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 14 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Las Vegas, Nevada
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Centanafadine Hydrochloride
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 18 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
84
States / cities
Dothan, Alabama • Saraland, Alabama • Phoenix, Arizona + 62 more
Completed Not applicable Interventional Results available

Brain Markers of Improvements in Cognitive Functioning

NCT03490110
Conditions
TBI (Traumatic Brain Injury), Brain Injuries, Stress, Attention Deficit, Executive Dysfunction
Interventions
State regulation skill training, Treatment-as-usual
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Bradenton, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SPN-810
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Conditions
ADHD
Interventions
Flashed Light Therapy, Videoconference-delivered Cognitive Behavioral Therapy
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
ADHD, Substance Abuse
Interventions
Methylphenidate (OROS-MPH), Methylphenidate (OROS-MPH) - Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years to 18 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
12
States / cities
Denver, Colorado • Jacksonville, Florida • St. Petersburg, Florida + 9 more
Completed Not applicable Interventional

Integrative Coping Group for Children

NCT01813669
Conditions
Childhood Depression, Childhood Anxiety, Pediatric Pain, Migraines, ADHD, Pediatric Stomach Pain, Musculoskeletal Pain
Interventions
Integrative Coping Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
10 Years to 12 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Intermittent Explosive Disorder, Childhood Aggression, Oppositional Defiant Disorder, Attention Deficit Disorder
Interventions
Parent Management Training, Placebo, Intuniv
Behavioral · Other · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Disruptive Behavior, Attention-deficit Hyperactivity, Oppositional Defiant Disorder
Interventions
Garmin
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-theanine, Caffeine, L-theanine-Caffeine Combination, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Tech University
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
EVO
Device
Lead sponsor
Akili Interactive Labs, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 9 more
Completed No phase listed Observational Accepts healthy volunteers

Adolescent Changes in Brain and Behavior in Boys and Girls With ADHD

NCT05927506
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Other
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas